CO4930260A1 - Metodos y composiciones para estimular el crecimiento de neuritas - Google Patents
Metodos y composiciones para estimular el crecimiento de neuritasInfo
- Publication number
- CO4930260A1 CO4930260A1 CO97066755A CO97066755A CO4930260A1 CO 4930260 A1 CO4930260 A1 CO 4930260A1 CO 97066755 A CO97066755 A CO 97066755A CO 97066755 A CO97066755 A CO 97066755A CO 4930260 A1 CO4930260 A1 CO 4930260A1
- Authority
- CO
- Colombia
- Prior art keywords
- straight
- branched
- alkyl
- alkenyl
- substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Una composición farmaceúticamente aceptable quecomprende: a) una cantidad neurotrofica de un compuesto que contiene la fórmula (I) y derivados farmaceúticamente aceptables de este, en donde: R1 B y D son independientemente: hidrógeno, Ar, alquilo (C1-C6) recto o ramificado, alquenilo o alquinilo (C2-C6) recto o ramificado, alquilo (C1-C6) recto o ramificado sustituido con cicloalquilo (C5- C7), alquenilo o alquinilo recto o ramificado (C3-C6) sustituido con cicloalquilo (C5-C7) alquilo recto o ramificado (C1-C6) sustituido con cicloalquilo (C5-C7), alquenilo o alquinilo recto o ramificado (C3-C6) sustituido con cicloalquenilo (C5-C7), alquilo recto o ramificado (C1-C6) sustituido con Ar, alquenilo o alquinilo recto o ramificado (C3-C6) sustituido con Ar; dado que R1 no es hidrógeno; en donde cualquiera de los grupos CH2 de dichas cadenas alquilo en R1 , B y D es opcionalmente reemplazado por O, S, SO, SO2 , o NR; en donde R es hidrógeno, alquilo recto o ramificado (C1-C6) alquenilo o alquinilo recto o ramificado (C3-C4), o alquilo puente (C1-C4). El alquilo puente (C1-C4), junto con el nitrógeno y un átomo de carbono de dicha cadena alquilo para formar un anillo, y en donde dicho anillo es opcionalmente fusionado a un Ar; En donde cada Ar es independientemente seleccionada de fenilo, 1-naftilo, 2-naftilo, indenilo, azulenilo, fluorenilo, antracenilo, 2-furilo, 3-furilo, 2-tienilo, 3-tienilo, 2-piridilo, 3-piridilo, 4- piridilo, pirrolilo, oxazolilo, thiazolilo, imidazolilo, pirazolilo, 2-pirazolinilo, - 2 -pirazolidinilo, isotriazolilo, 1,2,3-oxadiazolilo, 1,2,3-triazolilo, 1,2,4-tiadiazolilo, piridazinilo, pirimidinilo, pirazinilo, 1,3,5-triazinilo, 1,2,5-tritianilo, indolizinilo, indolilo, isoindolilo, 3H-indolilo, indolinilo, benzo [b] furanilo, benzo [b] tiofenilo, 1Hindazolilo, benzimidazolilo, benztiazolilo, purinilo, 4H- quinolizinilo, quinolinilo, 1,2,3,4-tetrahidro- isoquinolinilo, isoquinolinilo, 1,2,3,4-tetrahidro- isoquinolinilo, cinnolinilo, ftalazinilo, quinazolinilo, quinoxalinilo, 1,8-naftiridinilo, pteridinilo, carbazolilo, acridinilo, fenazinilo, fenotiazinilo y fenoxazinilo; y En donde cada Ar es opcionalmente e independientemente sustituido con uno a tres sustituyentes independientemente seleccionados de hidrógeno, halógeno, hidroxilo, nitro, -SO3 H, trifluorometilo, trifluorometoxi, alquilo recto o ramificado (C1-C6), O-(alquilo recto o ramificado (C1-C6), O-benzilo, O-fenilo, 1,2-metilenodioxi, -NR5 R6 , carboxilo, N-(alquilo recto o ramificado (C1-C6), N-(alquenilo recto o ramificado (C3-C5)) carboxamida, N,N- di(alquilo recto o ramificado (C1-C6)), N,N-di(alquenilo recto o ramificado (C3-C5)), carbozamida, morfolinilo, piperidinilo, O-M, CH2 -(CH2 )q -M, O-(CH2 )q - M,(CH2 )q -O-M, y CH=CH-M; en donde R5 y R6 son independientemente seleccionados del grupo que consiste de hidrógeno, alquilo, recto o ramificado (C1-C6), alquenilo o alquinilo recto o ramificado (C2-C6), benzilo o R5 y R son puestos juntos para formar un anillo heterocíclico de 5-7 miembros; M es seleccionado del grupo que consiste de 4-metoxifenilo, 2-piridilo, 3-piridilo, 4-piridilo, pirazilo, quinolilo, 3,5-dimetilisoxazoilo, 2- metiltioazoilo, tiazoilo, 2-tienilo, 3-tienilo, 4-tienilo y pirimidilo; y q es 0 - 2;J es seleccionado del grupo que consiste de alquilo recto o ramificado (C1AND#8209;C6), alquenilo o alquinilo recto o ramificado (C3AND#8209;C6), alquilo recto o ramificado (C1AND#8209;C6) sustituido con Ar, alquenilo o alquinilo recto o ramificado (C3AND#8209;C6) sustituido con Ar, y ciclohexilmetilo; K es seleccionado del grupo que consiste de alquilo recto o ramificado (C1AND#8209;C6), alquilo recto o ramificado (C1 AND#8209;C6 ) sustituido con Ar, alquenilo o alquinilo recto o ramificado (C2AND#8209;C6), o alquenilo o alquinilo recto o ramificado (C3AND#8209;C6) sustituido con Ar; J y K son tomados juntos con los átomos de nitrógeno y carbono a los cuales ellos están respectivamente unidos para formar un anillo heterocíclico de 5AND#8209;7 miembros que puede contener un heteroátomo seleccionado de O, S, SO y SO2 ; X es seleccionado del grupo que consiste de Ar, OR2 y AND#8209;NR3 R4 ; en donde R2 tiene la misma definición que R1 ; R3 y R4 independientemente tienen las mismas definiciones de B y D; o R3 y R4 pueden ser tomados juntos para formar un anillo alifático o aromático heterocíclico de 5AND#8209;7 miembros; y m es 0 ó 1 b) un factor neurotrópico; y c) un portador farmacéuticamente adecuado.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/748,447 US5840736A (en) | 1996-11-13 | 1996-11-13 | Methods and compositions for stimulating neurite growth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4930260A1 true CO4930260A1 (es) | 2000-06-27 |
Family
ID=25009484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO97066755A CO4930260A1 (es) | 1996-11-13 | 1997-11-13 | Metodos y composiciones para estimular el crecimiento de neuritas |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US5840736A (es) |
| EP (1) | EP0946190B1 (es) |
| JP (1) | JP2001504470A (es) |
| KR (1) | KR100544451B1 (es) |
| CN (1) | CN1168442C (es) |
| AP (1) | AP9901518A0 (es) |
| AR (1) | AR011278A1 (es) |
| AT (1) | ATE250424T1 (es) |
| AU (1) | AU724833B2 (es) |
| BG (1) | BG64670B1 (es) |
| BR (1) | BR9712765A (es) |
| CA (1) | CA2270634A1 (es) |
| CO (1) | CO4930260A1 (es) |
| CZ (1) | CZ296058B6 (es) |
| DE (1) | DE69725169T2 (es) |
| DK (1) | DK0946190T3 (es) |
| EA (1) | EA004247B1 (es) |
| ES (1) | ES2206753T3 (es) |
| HK (1) | HK1022851A1 (es) |
| HU (1) | HU226728B1 (es) |
| IL (1) | IL129555A (es) |
| IN (1) | IN183740B (es) |
| IS (1) | IS2057B (es) |
| NO (1) | NO328030B1 (es) |
| NZ (1) | NZ335394A (es) |
| PL (1) | PL190903B1 (es) |
| PT (1) | PT946190E (es) |
| SK (1) | SK284535B6 (es) |
| TR (1) | TR199901034T2 (es) |
| TW (1) | TW513302B (es) |
| UA (1) | UA63926C2 (es) |
| WO (1) | WO1998020891A1 (es) |
| ZA (1) | ZA9710256B (es) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859031A (en) | 1995-06-07 | 1999-01-12 | Gpi Nil Holdings, Inc. | Small molecule inhibitors of rotamase enzyme activity |
| US6242468B1 (en) | 1997-02-27 | 2001-06-05 | Jia-He Li | Carbamate and urea compositions and neurotrophic uses |
| US6514686B2 (en) | 1997-04-28 | 2003-02-04 | The University Of British Columbia | Method and composition for modulating amyloidosis |
| US5945441A (en) | 1997-06-04 | 1999-08-31 | Gpi Nil Holdings, Inc. | Pyrrolidine carboxylate hair revitalizing agents |
| US6852496B1 (en) * | 1997-08-12 | 2005-02-08 | Oregon Health And Science University | Methods of screening for agents that promote nerve cell growth |
| US5968921A (en) * | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
| JP2002516904A (ja) | 1998-06-03 | 2002-06-11 | ジーピーアイ ニル ホールディングス インコーポレイテッド | Ｎ−複素環式カルボン酸またはカルボン酸等配電子体のｎ−結合スルホンアミド |
| US6331537B1 (en) | 1998-06-03 | 2001-12-18 | Gpi Nil Holdings, Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds |
| AU756912B2 (en) | 1998-07-17 | 2003-01-23 | Agouron Pharmaceuticals, Inc. | Compounds, compositions, and methods for stimulating neuronal growth and elongation |
| GB9815880D0 (en) | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
| US6218423B1 (en) | 1998-08-14 | 2001-04-17 | Gpi Nil Holdings, Inc. | Pyrrolidine derivatives for vision and memory disorders |
| US6395758B1 (en) | 1998-08-14 | 2002-05-28 | Gpi Nil Holdings, Inc. | Small molecule carbamates or ureas for vision and memory disorders |
| US6462072B1 (en) | 1998-09-21 | 2002-10-08 | Gpi Nil Holdings, Inc. | Cyclic ester or amide derivatives |
| US6300341B1 (en) | 1998-09-30 | 2001-10-09 | The Procter & Gamble Co. | 2-substituted heterocyclic sulfonamides |
| US6307049B1 (en) | 1998-09-30 | 2001-10-23 | The Procter & Gamble Co. | Heterocyclic 2-substituted ketoamides |
| US6228872B1 (en) | 1998-11-12 | 2001-05-08 | Bristol-Myers Squibb Company | Neurotrophic diamide and carbamate agents |
| WO2000033814A2 (en) * | 1998-12-09 | 2000-06-15 | Chiron Corporation | Method for administering agents to the central nervous system |
| EP1140844A1 (en) * | 1999-01-08 | 2001-10-10 | Vertex Pharmaceuticals Incorporated | Process for the formation of intermediates useful for the preparation of pharmaceuticals |
| WO2001002368A1 (en) | 1999-07-06 | 2001-01-11 | Vertex Pharmaceuticals Incorporated | N-heterocyclic derivatives with neuronal activity |
| US6734211B1 (en) | 1999-07-09 | 2004-05-11 | Oregon Health & Sciences University | Compositions and methods for promoting nerve regeneration |
| WO2001008685A1 (en) * | 1999-07-30 | 2001-02-08 | Vertex Pharmaceuticals Incorporated | Acyclic and cyclic amine derivatives |
| US6417189B1 (en) | 1999-11-12 | 2002-07-09 | Gpi Nil Holdings, Inc. | AZA compounds, pharmaceutical compositions and methods of use |
| AR034103A1 (es) * | 1999-11-12 | 2004-02-04 | Alcon Inc | Composicion farmaceutica que comprende ligandos de neurofilina para el tratamiento de condiciones oculares |
| US7253169B2 (en) | 1999-11-12 | 2007-08-07 | Gliamed, Inc. | Aza compounds, pharmaceutical compositions and methods of use |
| US6818643B1 (en) | 1999-12-08 | 2004-11-16 | Bristol-Myers Squibb Company | Neurotrophic bicyclic diamides |
| US7060676B2 (en) | 1999-12-20 | 2006-06-13 | Trustees Of Tufts College | T. cruzi-derived neurotrophic agents and methods of use therefor |
| ATE319712T1 (de) | 1999-12-21 | 2006-03-15 | Mgi Gp Inc | Hydantoin derivate, pharmazeutische zusammensetzungen und verfahren zu ihrer verwendung |
| US6555573B2 (en) | 2000-12-21 | 2003-04-29 | The Quigley Corporation | Method and composition for the topical treatment of diabetic neuropathy |
| US7507799B2 (en) * | 2001-05-25 | 2009-03-24 | Cornell Research Foundation, Inc. | High affinity ligand for p75 neurotrophin receptor |
| FR2825273B1 (fr) * | 2001-05-29 | 2006-11-24 | Oreal | Composition pour le traitement des signes cutanes du vieillissement |
| JP2005500270A (ja) * | 2001-05-29 | 2005-01-06 | ギルフォード ファーマシュウティカルズ インコーポレイテッド | 手術の結果として発生した神経損傷を治療するための方法 |
| US20030105027A1 (en) * | 2001-11-06 | 2003-06-05 | Rosenbloom Richard A. | Nutritional supplements and methods for prevention, reduction and treatment of radiation injury |
| US20030118536A1 (en) * | 2001-11-06 | 2003-06-26 | Rosenbloom Richard A. | Topical compositions and methods for treatment of adverse effects of ionizing radiation |
| US7435725B2 (en) * | 2001-11-06 | 2008-10-14 | The Quigly Corporation | Oral compositions and methods for prevention, reduction and treatment of radiation injury |
| US7232798B2 (en) | 2001-11-13 | 2007-06-19 | Tran Loi H | Neuroprotection and neuroegenisis by administering cyclic prolyl glycine |
| US20100247483A1 (en) * | 2001-11-13 | 2010-09-30 | Tran Loi H | Therapeutic agent composition and method of use |
| WO2003041655A2 (en) * | 2001-11-13 | 2003-05-22 | Loi Tran | Therapeutic agent composition and method of use |
| US7083813B2 (en) * | 2002-11-06 | 2006-08-01 | The Quigley Corporation | Methods for the treatment of peripheral neural and vascular ailments |
| US8841326B2 (en) | 2004-02-12 | 2014-09-23 | Stc.Unm | Therapeutic curcumin derivatives |
| EP1988920A1 (en) * | 2006-02-02 | 2008-11-12 | Rinat Neuroscience Corp. | Methods for treating obesity by administering a trkb antagonist |
| CN101400367A (zh) * | 2006-02-02 | 2009-04-01 | 瑞纳神经科学公司 | 施用trkb激动剂治疗不希望的重量减轻或进食障碍的方法 |
| JP2010513461A (ja) * | 2006-12-20 | 2010-04-30 | ライナット ニューロサイエンス コーポレイション | 自己免疫障害を治療するためのＴｒｋＢアゴニスト |
| US20090018151A1 (en) * | 2007-02-23 | 2009-01-15 | Ezekiel Fink | Topical Treatment of Peripheral diabetic complications |
| US11090303B2 (en) | 2018-05-15 | 2021-08-17 | Lloyd Hung Loi Tran | Therapeutic agent composition and method of use, for treatment of mild congnitive impairment, depression, and psychological disorders |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5798355A (en) | 1995-06-07 | 1998-08-25 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity |
| IL115685A (en) * | 1994-11-16 | 2000-08-31 | Vertex Pharma | Amino acid derivatives pharmaceutical compositions containing the same and processes for the preparation thereof |
| US5543423A (en) * | 1994-11-16 | 1996-08-06 | Vertex Pharmaceuticals, Incorporated | Amino acid derivatives with improved multi-drug resistance activity |
| US5696135A (en) * | 1995-06-07 | 1997-12-09 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth |
| US5859031A (en) * | 1995-06-07 | 1999-01-12 | Gpi Nil Holdings, Inc. | Small molecule inhibitors of rotamase enzyme activity |
| US5614547A (en) * | 1995-06-07 | 1997-03-25 | Guilford Pharmaceuticals Inc. | Small molecule inhibitors of rotamase enzyme |
| US6037370A (en) * | 1995-06-08 | 2000-03-14 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
| US5801197A (en) | 1995-10-31 | 1998-09-01 | Gpi Nil Holdings, Inc. | Rotamase enzyme activity inhibitors |
| US5811434A (en) * | 1996-11-13 | 1998-09-22 | Vertex Pharmacueticals Incorporated | Methods and compositions for stimulating neurite growth |
| WO2014051091A1 (ja) * | 2012-09-28 | 2014-04-03 | Dic株式会社 | α－アルミナ微粒子及びその製造方法 |
-
1996
- 1996-11-13 US US08/748,447 patent/US5840736A/en not_active Expired - Lifetime
-
1997
- 1997-11-13 TW TW086116911A patent/TW513302B/zh not_active IP Right Cessation
- 1997-11-13 CZ CZ0168399A patent/CZ296058B6/cs not_active IP Right Cessation
- 1997-11-13 NZ NZ335394A patent/NZ335394A/en unknown
- 1997-11-13 HU HU0001219A patent/HU226728B1/hu not_active IP Right Cessation
- 1997-11-13 ZA ZA9710256A patent/ZA9710256B/xx unknown
- 1997-11-13 DK DK97947533T patent/DK0946190T3/da active
- 1997-11-13 PL PL333270A patent/PL190903B1/pl not_active IP Right Cessation
- 1997-11-13 AP APAP/P/1999/001518A patent/AP9901518A0/en unknown
- 1997-11-13 CA CA002270634A patent/CA2270634A1/en not_active Abandoned
- 1997-11-13 BR BR9712765-5A patent/BR9712765A/pt not_active IP Right Cessation
- 1997-11-13 IL IL12955597A patent/IL129555A/xx not_active IP Right Cessation
- 1997-11-13 JP JP52286598A patent/JP2001504470A/ja active Pending
- 1997-11-13 SK SK628-99A patent/SK284535B6/sk not_active IP Right Cessation
- 1997-11-13 PT PT97947533T patent/PT946190E/pt unknown
- 1997-11-13 ES ES97947533T patent/ES2206753T3/es not_active Expired - Lifetime
- 1997-11-13 WO PCT/US1997/020866 patent/WO1998020891A1/en active IP Right Grant
- 1997-11-13 EP EP97947533A patent/EP0946190B1/en not_active Expired - Lifetime
- 1997-11-13 AT AT97947533T patent/ATE250424T1/de not_active IP Right Cessation
- 1997-11-13 AR ARP970105318A patent/AR011278A1/es unknown
- 1997-11-13 CN CNB971802467A patent/CN1168442C/zh not_active Expired - Fee Related
- 1997-11-13 CO CO97066755A patent/CO4930260A1/es unknown
- 1997-11-13 TR TR1999/01034T patent/TR199901034T2/xx unknown
- 1997-11-13 UA UA99063268A patent/UA63926C2/uk unknown
- 1997-11-13 AU AU52589/98A patent/AU724833B2/en not_active Ceased
- 1997-11-13 EA EA199900464A patent/EA004247B1/ru not_active IP Right Cessation
- 1997-11-13 DE DE69725169T patent/DE69725169T2/de not_active Expired - Lifetime
- 1997-11-13 IN IN2149CA1997 patent/IN183740B/en unknown
- 1997-11-13 KR KR1019997004186A patent/KR100544451B1/ko not_active IP Right Cessation
-
1998
- 1998-11-23 US US09/198,175 patent/US6172086B1/en not_active Expired - Lifetime
-
1999
- 1999-04-21 IS IS5032A patent/IS2057B/is unknown
- 1999-05-03 NO NO19992138A patent/NO328030B1/no not_active IP Right Cessation
- 1999-05-25 BG BG103429A patent/BG64670B1/bg unknown
-
2000
- 2000-04-05 HK HK00102067A patent/HK1022851A1/xx not_active IP Right Cessation
- 2000-10-03 US US09/678,265 patent/US6284778B1/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4930260A1 (es) | Metodos y composiciones para estimular el crecimiento de neuritas | |
| CO5080733A1 (es) | Metodos y composiciones para estimular el crecimiento de neuritas | |
| CO4920219A1 (es) | Metodos y composiciones para estimular el crecimiento de neuritas | |
| CO5080734A1 (es) | Compuestos amino que poseen actividad neuronal | |
| RU97110114A (ru) | Новые производные аминокислот с повышенной активностью против множественной лекарственной устойчивости | |
| BR9803883A (pt) | Derivado de amida. | |
| NO302570B1 (no) | Substituerte pipekolinsyrederivater som HIV-protease-inhibitorer, farmasöytiske blandinger inneholdende dem og anvendelser av derivatene | |
| DK0496796T3 (da) | Fremgangsmåde og præparater til inhibering af sygdomme i forbindelse med oxidativ beskadigelse | |
| HUP0400694A2 (hu) | A rotamáz enzim aktivitásának kis molekulájú inhibitorai, valamint ezeket a vegyületeket tartalmazó gyógyászati készítmények | |
| HUP0001652A2 (hu) | Oxadiazolszármazékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| BR0212829A (pt) | Derivados de 1,8-naftiridina e seu uso para tratar diabetes e distúrbios relacionados | |
| CO4950619A1 (es) | Derivados de acido arilsulfonil hidroxamico | |
| AR006867A1 (es) | Composición topica para la piel que comprende un compuesto oxa-diácido, su uso para preparar un medicamento para tratar condiciones de la piel y métodos cosméticos no terapéuticos para el pulido de la piel y para suavizar el cabello que aplican dicho compuesto. | |
| AR029806A1 (es) | Derivados de fenilo, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de la composicion farmaceutica y usos de estos derivados | |
| AR033408A1 (es) | Compuestos de bisarilo que contienen nitrogeno orto, orto-sustituidos, procedimientos para su preparacion, su utilizacion para la preparacion de un medicamento como tambien composiciones farmaceuticas que los contienen | |
| ES2137998T3 (es) | Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos. | |
| ES2174579T3 (es) | Nuevos derivados benzotiofenicos, benzofuranicos e indolicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| ES2102154T3 (es) | Inhibicion de trombina. | |
| DE60041763D1 (de) | Inhibitoren von c-jun n-terminal kinasen (jnk) | |
| AU8021594A (en) | New naphthalene derivatives, processes for their preparation and the pharmaceutical compositions which contain them | |
| NO984740L (no) | Isatinderivater som acetylcholinesteraseinhibitorer og analgetiske midler | |
| DK0602028T3 (da) | Aromatiske sulfonamidderivater, deres anvendelse som enzyminhibitorer og farmaceutiske præparater me d indhold deraf | |
| AR002745A1 (es) | 5,6-DIHIDRO-9H-PIRAZOL[3,4-c]-1,2,4-TRIAZOL [4,3-a] PIRIDINAS TRICICLICAS Y COMPOSICIONES FARMACEUTICAS CONTENIENDO LAS MISMAS. | |
| AR010377A1 (es) | Composiciones farmaceuticas para secar por congelacion que contienen compuestos de nucleosidos, procedimiento para su preparacion y uso de dichas composiciones para fabricar medicamentos. | |
| EE04058B1 (et) | Benso[c]kinolisiini derivaadid, nende valmistamine ja kasutamine 5a-reduktaasi inhibiitoritena |